We are proud to celebrate a fantastic achievement here at Pamex, as Utipro® Plus AF has been named Best Women’s Product at the OTC Awards with the Irish Pharmacy News.

This award recognises excellence in innovation, effectiveness, and patient care within the pharmacy sector, and highlights the important role Utipro® Plus AF plays in supporting women’s health.

Product Overview

Utipro® Plus AF is a clinically supported, antibiotic-free solution designed to provide both relief of acute cystitis symptoms and prevention of recurrent urinary tract infections (UTIs). UTIs are one of the most common infections in women, with a significant proportion arising from bacteria originating in the bowel. Utipro Plus AF offers a dual mode of action that works in both the bowel and the bladder. In the bowel, it creates a protective film to reduce bacterial growth and prevent bacteria from ascending to the bladder. In the bladder, it helps create conditions that are less conducive to bacterial growth, supporting clearance of the infection and relief of symptoms. This dual mechanism allows it to address both acute symptom relief and recurrence prevention, providing a comprehensive, non-antibiotic approach to UTI management.

Objectives of Utipro® Plus AF

• Provide effective symptom relief for acute cystitis.
• Reduce recurrence of UTIs by targeting the primary source of infection in the intestine.
• Support antimicrobial stewardship by offering a clinically validated, antibiotic-free alternative.
• Empower women with a proactive and evidence-based option for urinary health management.

Unique Selling Points

Utipro Plus AF stands out as the only non-antibiotic treatment currently available in Ireland that directly targets the source of infection in the intestine by creating a protective layer, while supporting a bladder environment that discourages bacterial growth. Its unique dual mode of action distinguishes it from other UTI treatments:

• Dual Action: Works in both the bowel and bladder, addressing both acute symptoms and recurrence prevention.
• Source-Targeted Approach: Reduces bacterial growth in the intestine and limits their ability to ascend to the bladder.
• Antibiotic-Free: Provides an evidence-based option in line with antimicrobial stewardship initiatives.
• Evidence-Based: Backed by gold-standard randomized controlled trials (RCTs), observational studies, and large real-world evidence (RWE) datasets. Also recognised in the 2025 European Association of Urology (EAU) guidelines for its effectiveness in cystitis management (level of supporting evidence graded at the highest level -LE 1a)
• Positive Pilot Outcomes in Ireland: Recent pilot studies in Irish nursing homes have shown reduced UTI rates and decreased need for prophylactic antibiotic use. These findings indicate that its benefits are seen not only in the broader female population but also among elderly women.

Innovation

Utipro Plus AF represents an innovative approach in UTI management: rather than focusing solely on treating infections once they reach the bladder, it targets the primary source of most infections—the intestine, while also supporting a bladder environment that helps clear the infection. This preventative and symptom-relieving mechanism is a novel concept in cystitis management and sets Utipro Plus AF apart from other treatments. By providing a clinically supported, non-antibiotic option, the product addresses the urgent public health challenge of antimicrobial resistance and aligns with global efforts to promote responsible antibiotic use.

Investment in the Brand

Significant investment has been made to support the growth, visibility, and impact of Utipro Plus AF across both the healthcare and consumer landscape:

• Medical Promotion: Engagement with primary and secondary care HCPs
• Educational webinars
• Consumer Marketing: Multi-channel campaigns including social media, influencer partnerships, podcast sponsorships

Support to Pharmacy

Utipro Plus AF is supported with a comprehensive package for pharmacies:

• Point-of-Sale Materials: Shelf edgers and attractive display units
• Leaflets for patients to understand the product and its use
• Promotional Offers
• Digital Assets: Graphics, social media content, and educational materials to support consumer engagement
• Pharmacy training sessions for staff

Brand History

Utipro Plus AF has established a strong track record since its introduction to the Irish market in 2021, providing a safe, evidence-based option for UTIs. Its introduction was guided by robust clinical evidence and a clear commitment to antimicrobial stewardship, positioning it as a trusted solution for both consumers and healthcare professionals. Over time, Utipro Plus AF has become a recognized name in urinary health, offering a unique combination of symptom relief, recurrence prevention, and antibiotic-free management, distinguishing it from other products on the market.

Why Utipro® Plus AF Deserves this Award

Utipro Plus AF represents an innovative, evidence-based, and patient-centered approach to UTI management. Its dual mode of action, targeting both the bowel and the bladder, addresses the root cause of most infections while creating an environment in the bladder that helps clear the infection. In a healthcare landscape increasingly focused on responsible antibiotic use, Utipro Plus AF offers an effective option, contributing to antimicrobial stewardship goals.

The product’s strong clinical backing, including gold-standard RCTs, observational studies, and real-world evidence, along with recognition in EAU guidelines, underscores its credibility and effectiveness. In addition, the level of investment in consumer and HCP engagement, marketing, and pharmacy support demonstrates a commitment to ensuring Utipro Plus AF reaches the patients who need it.

Utipro Plus AF is a forward-thinking solution addressing a common and significant healthcare challenge. By combining clinical innovation, robust evidence, and strong HCP endorsement, Utipro Plus AF demonstrates excellence in patient care and antimicrobial stewardship, qualities that make it the deserving winner for this award.

Celebrating Success at Pamex

We are incredibly proud here at Pamex to celebrate this achievement. Winning Best Women’s Product at the OTC Awards is a testament to the strength of the product, the science behind it, and the impact it continues to make in women’s health.

Congratulations to everyone involved in bringing Utipro® Plus AF to this level of success!